Content area

|
|

Udredning, behandling og opfølgning af vulvacancer

Forfatter(e)
Ligita Paskeviciute Frøding1, *, Vibeke Zobbe1, *, Lars Ulrik Fokdal2, *, Isa Charlotte Secher Niemann3, *, Trine Jakobi Nøtrup4, *, Elisabeth Kristensen5, *,
Anne Pernille Christiansen5, *, Annika Loft6, * & Tine Henrichsen Schnack1, * 1) Gynækologisk Afdeling, Rigshospitalet2) Onkologisk Afdeling, Aarhus Universitets-hospital3) Gynækologisk Afdeling, Aarhus Universitetshospital4) Onkologisk Afdeling, Rigshospitalet5) Patologiafdelingen, Rigshospitalet6) Klinisk Fysiologi, Nuklearmedicin og PET, Rigshospitalet

Ugeskr Læger 2019;181:V04190216
Reference: 
Ugeskr Læger 2019;181:V04190216
Sidetal: 

Ligita Paskeviciute Frøding*, Vibeke Zobbe*, Lars Ulrik Fokdal*,
Isa Charlotte Secher Niemann*, Trine Jakobi Nøtrup*,
Elisabeth Kristensen*, Anne Pernille Christiansen*, Annika Loft* & Tine Henrichsen Schnack*:

Work-up, treatment and follow-up of vulva cancer

Ugeskr Læger 2019;181:V04190216

This review summarises the current guidelines for vulva cancer in Denmark. Vulva cancer is a rare disease. The diagnosis is often delayed, which results in large tumours and regional spread. The most important prognostic factor is inguinal lymph node metastases. Staging and treatment is centralised to two hospitals. Primary treatment is wide local excision combined with removal of either inguinal sentinel nodes or lymphadenectomy. Treatment is associated with considerable morbidity, and supportive care is often necessary. Local curable recurrences are common. Relapses in the groin are associated with a poor prognosis. Thus, long term follow-up is essential.

*) On behalf of Dansk Gynækologisk Cancer Gruppe for vulvacancer

Du skal være logget ind for at læse denne artikel
Log ind

Right side